| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukoencephalopathy, Progressive Multifocal | 93 | 2021 | 111 | 22.590 |
Why?
|
| JC Virus | 79 | 2021 | 97 | 17.830 |
Why?
|
| CD8-Positive T-Lymphocytes | 13 | 2023 | 111 | 3.810 |
Why?
|
| HIV Infections | 33 | 2022 | 466 | 3.590 |
Why?
|
| Polyomavirus Infections | 20 | 2018 | 26 | 3.540 |
Why?
|
| DNA, Viral | 20 | 2019 | 40 | 3.190 |
Why?
|
| Humans | 182 | 2023 | 27072 | 3.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2021 | 85 | 2.990 |
Why?
|
| Capsid Proteins | 16 | 2019 | 27 | 2.800 |
Why?
|
| Neurons | 10 | 2019 | 339 | 2.630 |
Why?
|
| Brain | 30 | 2020 | 1649 | 2.590 |
Why?
|
| AIDS-Related Opportunistic Infections | 11 | 2015 | 40 | 2.520 |
Why?
|
| Nervous System Diseases | 6 | 2021 | 117 | 2.450 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 8 | 2017 | 13 | 2.330 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2023 | 102 | 2.330 |
Why?
|
| Brain Diseases | 8 | 2021 | 66 | 2.300 |
Why?
|
| Seizures | 13 | 2022 | 67 | 2.200 |
Why?
|
| Multiple Sclerosis | 8 | 2020 | 89 | 2.160 |
Why?
|
| Adult | 69 | 2022 | 7831 | 2.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 13 | 2009 | 23 | 2.080 |
Why?
|
| Tuberculosis, Meningeal | 3 | 2021 | 4 | 2.040 |
Why?
|
| Male | 89 | 2022 | 14772 | 2.010 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 7 | 2021 | 11 | 1.940 |
Why?
|
| Acquired Immunodeficiency Syndrome | 11 | 2015 | 41 | 1.880 |
Why?
|
| Neurology | 4 | 2022 | 37 | 1.820 |
Why?
|
| Female | 70 | 2022 | 15212 | 1.600 |
Why?
|
| Middle Aged | 55 | 2022 | 8923 | 1.580 |
Why?
|
| Disease Progression | 15 | 2023 | 673 | 1.550 |
Why?
|
| HIV Seropositivity | 9 | 2013 | 49 | 1.500 |
Why?
|
| Immunity, Cellular | 9 | 2013 | 32 | 1.450 |
Why?
|
| Magnetic Resonance Imaging | 28 | 2020 | 1112 | 1.390 |
Why?
|
| Fatigue | 4 | 2023 | 57 | 1.300 |
Why?
|
| Antibodies, Viral | 11 | 2023 | 55 | 1.260 |
Why?
|
| Spinal Cord | 4 | 2015 | 84 | 1.250 |
Why?
|
| Remote Consultation | 2 | 2022 | 11 | 1.250 |
Why?
|
| Zambia | 15 | 2022 | 17 | 1.250 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 86 | 1.220 |
Why?
|
| Simian virus 40 | 6 | 2015 | 10 | 1.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 90 | 1.220 |
Why?
|
| Natalizumab | 11 | 2019 | 18 | 1.210 |
Why?
|
| Immunologic Factors | 5 | 2021 | 29 | 1.160 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 177 | 1.160 |
Why?
|
| Cerebral Cortex | 4 | 2014 | 155 | 1.100 |
Why?
|
| BK Virus | 8 | 2014 | 12 | 1.080 |
Why?
|
| Sequence Deletion | 4 | 2012 | 16 | 1.070 |
Why?
|
| Cerebellum | 6 | 2013 | 43 | 0.990 |
Why?
|
| Tumor Virus Infections | 7 | 2014 | 17 | 0.970 |
Why?
|
| HIV Seronegativity | 5 | 2014 | 18 | 0.960 |
Why?
|
| Aged | 34 | 2021 | 8997 | 0.960 |
Why?
|
| Young Adult | 16 | 2021 | 1994 | 0.950 |
Why?
|
| Viral Proteins | 4 | 2015 | 13 | 0.910 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 4 | 2015 | 16 | 0.890 |
Why?
|
| Cognitive Dysfunction | 3 | 2023 | 1061 | 0.880 |
Why?
|
| Headache | 2 | 2021 | 35 | 0.870 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2015 | 14 | 0.870 |
Why?
|
| Capsid | 5 | 2014 | 13 | 0.860 |
Why?
|
| Viral Regulatory and Accessory Proteins | 4 | 2013 | 11 | 0.860 |
Why?
|
| Mitochondrial Proteins | 1 | 2023 | 41 | 0.860 |
Why?
|
| Antigens, Viral, Tumor | 7 | 2019 | 11 | 0.850 |
Why?
|
| Olfaction Disorders | 2 | 2020 | 49 | 0.840 |
Why?
|
| Genotype | 2 | 2021 | 346 | 0.840 |
Why?
|
| Narcolepsy | 2 | 2019 | 6 | 0.820 |
Why?
|
| Kidney Transplantation | 7 | 2017 | 119 | 0.810 |
Why?
|
| HIV-1 | 7 | 2017 | 221 | 0.810 |
Why?
|
| HIV-2 | 3 | 2017 | 10 | 0.800 |
Why?
|
| Betacoronavirus | 2 | 2020 | 74 | 0.800 |
Why?
|
| Internship and Residency | 2 | 2017 | 211 | 0.800 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 4 | 2008 | 8 | 0.790 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2012 | 34 | 0.790 |
Why?
|
| Viral Load | 12 | 2020 | 69 | 0.770 |
Why?
|
| Oligodendroglia | 4 | 2019 | 36 | 0.760 |
Why?
|
| Anticonvulsants | 4 | 2020 | 56 | 0.760 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2019 | 9 | 0.760 |
Why?
|
| Epoxide Hydrolases | 1 | 2021 | 11 | 0.760 |
Why?
|
| Molecular Sequence Data | 16 | 2012 | 195 | 0.750 |
Why?
|
| Interferon-gamma | 2 | 2019 | 81 | 0.750 |
Why?
|
| Dizziness | 2 | 2023 | 18 | 0.750 |
Why?
|
| Retrospective Studies | 15 | 2023 | 3538 | 0.720 |
Why?
|
| Dysgeusia | 1 | 2020 | 1 | 0.710 |
Why?
|
| Myalgia | 1 | 2020 | 1 | 0.710 |
Why?
|
| Animals | 19 | 2023 | 3642 | 0.710 |
Why?
|
| Orexins | 2 | 2019 | 3 | 0.710 |
Why?
|
| Choroid Plexus | 2 | 2021 | 7 | 0.690 |
Why?
|
| Prospective Studies | 9 | 2023 | 1778 | 0.670 |
Why?
|
| Coinfection | 4 | 2019 | 20 | 0.670 |
Why?
|
| Autoimmunity | 1 | 2019 | 13 | 0.660 |
Why?
|
| Virus Latency | 2 | 2010 | 15 | 0.660 |
Why?
|
| Dimethyl Fumarate | 2 | 2019 | 2 | 0.660 |
Why?
|
| Astrocytes | 3 | 2021 | 144 | 0.650 |
Why?
|
| Meninges | 2 | 2019 | 8 | 0.650 |
Why?
|
| T-Lymphocytes | 6 | 2014 | 96 | 0.650 |
Why?
|
| Global Health | 2 | 2017 | 36 | 0.640 |
Why?
|
| Henipavirus Infections | 1 | 2019 | 1 | 0.640 |
Why?
|
| Immunoassay | 1 | 2019 | 38 | 0.640 |
Why?
|
| Telemedicine | 1 | 2021 | 97 | 0.630 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 94 | 0.630 |
Why?
|
| Quality of Life | 5 | 2023 | 629 | 0.630 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2019 | 61 | 0.620 |
Why?
|
| Inflammation | 4 | 2020 | 272 | 0.610 |
Why?
|
| Virus Activation | 4 | 2014 | 11 | 0.610 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 189 | 0.610 |
Why?
|
| Follow-Up Studies | 10 | 2022 | 1792 | 0.610 |
Why?
|
| Bone Marrow | 2 | 2009 | 76 | 0.600 |
Why?
|
| Anti-Retroviral Agents | 2 | 2015 | 17 | 0.590 |
Why?
|
| Survivors | 3 | 2015 | 70 | 0.590 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 44 | 0.580 |
Why?
|
| Amino Acid Sequence | 11 | 2012 | 156 | 0.580 |
Why?
|
| HLA-A Antigens | 6 | 2010 | 12 | 0.570 |
Why?
|
| Polymerase Chain Reaction | 11 | 2014 | 120 | 0.560 |
Why?
|
| Meningitis, Aseptic | 2 | 2014 | 4 | 0.550 |
Why?
|
| Case-Control Studies | 6 | 2021 | 587 | 0.550 |
Why?
|
| Neuroglia | 3 | 2021 | 48 | 0.540 |
Why?
|
| Health Resources | 1 | 2017 | 23 | 0.540 |
Why?
|
| Program Development | 1 | 2017 | 51 | 0.540 |
Why?
|
| Anti-HIV Agents | 5 | 2020 | 64 | 0.530 |
Why?
|
| Cerebellar Diseases | 2 | 2018 | 8 | 0.530 |
Why?
|
| Human T-lymphotropic virus 1 | 7 | 1997 | 9 | 0.510 |
Why?
|
| Genes, Viral | 3 | 2018 | 7 | 0.510 |
Why?
|
| Biomarkers | 6 | 2022 | 562 | 0.510 |
Why?
|
| Thymus Gland | 1 | 2015 | 11 | 0.500 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2013 | 18 | 0.500 |
Why?
|
| Virus Diseases | 2 | 2021 | 11 | 0.490 |
Why?
|
| Luminescent Proteins | 1 | 2015 | 7 | 0.490 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 4777 | 0.490 |
Why?
|
| Genes, Reporter | 1 | 2015 | 22 | 0.490 |
Why?
|
| Psoriasis | 1 | 2015 | 12 | 0.480 |
Why?
|
| Prognosis | 8 | 2021 | 785 | 0.480 |
Why?
|
| Dura Mater | 1 | 2015 | 16 | 0.480 |
Why?
|
| Rare Diseases | 1 | 2015 | 13 | 0.480 |
Why?
|
| Lymphopenia | 4 | 2019 | 6 | 0.470 |
Why?
|
| Stroke | 4 | 2022 | 261 | 0.470 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2005 | 15 | 0.470 |
Why?
|
| Fatal Outcome | 9 | 2016 | 54 | 0.470 |
Why?
|
| Pandemics | 3 | 2022 | 236 | 0.470 |
Why?
|
| Adolescent | 10 | 2019 | 2172 | 0.460 |
Why?
|
| Viremia | 2 | 2011 | 8 | 0.460 |
Why?
|
| Hydrocephalus | 1 | 2014 | 18 | 0.460 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2007 | 11 | 0.450 |
Why?
|
| HIV | 4 | 2019 | 39 | 0.450 |
Why?
|
| Opportunistic Infections | 4 | 2009 | 7 | 0.450 |
Why?
|
| Herpesviridae | 1 | 2014 | 2 | 0.450 |
Why?
|
| Central Nervous System Infections | 1 | 2014 | 4 | 0.450 |
Why?
|
| DNA | 1 | 2014 | 106 | 0.440 |
Why?
|
| Virus Assembly | 1 | 2013 | 2 | 0.440 |
Why?
|
| Risk Factors | 9 | 2020 | 2302 | 0.440 |
Why?
|
| Methylprednisolone | 2 | 2016 | 20 | 0.440 |
Why?
|
| Virion | 1 | 2013 | 15 | 0.440 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2013 | 13 | 0.440 |
Why?
|
| ABO Blood-Group System | 1 | 2013 | 4 | 0.430 |
Why?
|
| Spinocerebellar Degenerations | 1 | 2013 | 4 | 0.430 |
Why?
|
| Bacterial Infections | 1 | 2014 | 51 | 0.430 |
Why?
|
| Kidney Diseases | 4 | 2008 | 72 | 0.420 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 11 | 0.420 |
Why?
|
| Polyomavirus | 4 | 2011 | 5 | 0.410 |
Why?
|
| Pyramidal Cells | 2 | 2012 | 34 | 0.410 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 109 | 0.400 |
Why?
|
| Virus Replication | 6 | 2013 | 51 | 0.400 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2013 | 259 | 0.400 |
Why?
|
| Cell Line | 7 | 2021 | 273 | 0.390 |
Why?
|
| AIDS Dementia Complex | 3 | 2022 | 39 | 0.390 |
Why?
|
| Base Sequence | 9 | 2012 | 109 | 0.380 |
Why?
|
| Encephalitis | 3 | 2020 | 11 | 0.380 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2011 | 1 | 0.380 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 11 | 0.380 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 115 | 0.380 |
Why?
|
| Survival Rate | 4 | 2021 | 342 | 0.370 |
Why?
|
| Tandem Repeat Sequences | 3 | 2012 | 4 | 0.360 |
Why?
|
| Neurosyphilis | 2 | 2021 | 3 | 0.350 |
Why?
|
| Treponema pallidum | 2 | 2021 | 4 | 0.350 |
Why?
|
| Phenotype | 2 | 2013 | 312 | 0.350 |
Why?
|
| Antiviral Agents | 5 | 2015 | 50 | 0.350 |
Why?
|
| Genome, Viral | 3 | 2012 | 13 | 0.340 |
Why?
|
| Developing Countries | 1 | 2010 | 12 | 0.340 |
Why?
|
| Immune Tolerance | 1 | 2009 | 14 | 0.330 |
Why?
|
| Communicable Diseases | 1 | 2010 | 23 | 0.330 |
Why?
|
| Integrin alpha4 | 1 | 2009 | 3 | 0.330 |
Why?
|
| COS Cells | 3 | 2014 | 42 | 0.330 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 366 | 0.330 |
Why?
|
| HLA-A2 Antigen | 3 | 2008 | 5 | 0.330 |
Why?
|
| Kidney | 4 | 2017 | 153 | 0.320 |
Why?
|
| Terminology as Topic | 2 | 2006 | 32 | 0.310 |
Why?
|
| Prevalence | 4 | 2021 | 443 | 0.310 |
Why?
|
| Hospitals | 1 | 2010 | 167 | 0.310 |
Why?
|
| Dendritic Cells | 1 | 2008 | 33 | 0.310 |
Why?
|
| Diagnosis, Differential | 5 | 2023 | 348 | 0.300 |
Why?
|
| Lymphoma | 2 | 2007 | 35 | 0.300 |
Why?
|
| Neurologic Examination | 4 | 2013 | 100 | 0.290 |
Why?
|
| Genetic Variation | 2 | 2006 | 96 | 0.290 |
Why?
|
| Ataxia | 2 | 2020 | 76 | 0.290 |
Why?
|
| Electroencephalography | 5 | 2015 | 77 | 0.290 |
Why?
|
| Neuroimaging | 5 | 2021 | 126 | 0.290 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2019 | 17 | 0.270 |
Why?
|
| Child | 6 | 2022 | 1295 | 0.270 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2020 | 53 | 0.270 |
Why?
|
| Time Factors | 4 | 2014 | 1433 | 0.270 |
Why?
|
| Disease Models, Animal | 5 | 2015 | 599 | 0.270 |
Why?
|
| Immunotherapy | 3 | 2016 | 58 | 0.260 |
Why?
|
| Immunosuppressive Agents | 4 | 2019 | 120 | 0.260 |
Why?
|
| Antibody Formation | 1 | 2006 | 17 | 0.260 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2012 | 39 | 0.260 |
Why?
|
| Epilepsy | 2 | 2020 | 60 | 0.250 |
Why?
|
| Nervous System | 2 | 2019 | 11 | 0.240 |
Why?
|
| Autopsy | 2 | 2019 | 344 | 0.240 |
Why?
|
| Sequence Alignment | 4 | 2011 | 19 | 0.240 |
Why?
|
| Cells, Cultured | 5 | 2008 | 520 | 0.240 |
Why?
|
| Hepatitis C | 1 | 2005 | 32 | 0.240 |
Why?
|
| Immunocompromised Host | 4 | 2017 | 46 | 0.240 |
Why?
|
| Recombination, Genetic | 2 | 2015 | 6 | 0.230 |
Why?
|
| Inositol | 1 | 2004 | 6 | 0.230 |
Why?
|
| Capillary Leak Syndrome | 1 | 2004 | 1 | 0.230 |
Why?
|
| Aspartic Acid | 1 | 2004 | 13 | 0.230 |
Why?
|
| Macaca mulatta | 5 | 2013 | 60 | 0.230 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 17 | 0.230 |
Why?
|
| Simian Immunodeficiency Virus | 3 | 2013 | 13 | 0.220 |
Why?
|
| Paresis | 1 | 2004 | 17 | 0.220 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2010 | 28 | 0.220 |
Why?
|
| Liver Transplantation | 1 | 2005 | 89 | 0.220 |
Why?
|
| Genes, pX | 3 | 1997 | 3 | 0.220 |
Why?
|
| Treatment Outcome | 8 | 2021 | 3485 | 0.220 |
Why?
|
| Mice | 6 | 2023 | 1395 | 0.210 |
Why?
|
| Immunity | 1 | 2023 | 15 | 0.210 |
Why?
|
| Antigens, Viral | 3 | 2013 | 9 | 0.210 |
Why?
|
| Proteome | 1 | 2023 | 41 | 0.210 |
Why?
|
| Biopsy | 5 | 2017 | 201 | 0.210 |
Why?
|
| Endogenous Retroviruses | 1 | 2003 | 2 | 0.210 |
Why?
|
| Ki-1 Antigen | 1 | 2003 | 2 | 0.210 |
Why?
|
| Chicago | 3 | 2022 | 949 | 0.210 |
Why?
|
| Interleukin-6 | 1 | 2023 | 74 | 0.210 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2003 | 15 | 0.210 |
Why?
|
| Nucleocapsid | 1 | 2022 | 2 | 0.210 |
Why?
|
| Dysarthria | 1 | 2022 | 2 | 0.210 |
Why?
|
| 2',3'-Cyclic-Nucleotide Phosphodiesterases | 2 | 2015 | 4 | 0.200 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2022 | 2 | 0.200 |
Why?
|
| Proteomics | 1 | 2023 | 89 | 0.200 |
Why?
|
| Skin Diseases | 1 | 2003 | 25 | 0.200 |
Why?
|
| Leukocytes | 2 | 2019 | 34 | 0.200 |
Why?
|
| Deglutition Disorders | 1 | 2022 | 31 | 0.200 |
Why?
|
| Meningitis | 1 | 2022 | 10 | 0.200 |
Why?
|
| Interferon-beta | 2 | 2014 | 8 | 0.200 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 2008 | 6 | 0.200 |
Why?
|
| Delirium | 1 | 2022 | 12 | 0.200 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 482 | 0.200 |
Why?
|
| Epitopes | 3 | 2008 | 46 | 0.190 |
Why?
|
| Transcription Factors | 3 | 2004 | 169 | 0.190 |
Why?
|
| Crotonates | 1 | 2021 | 3 | 0.190 |
Why?
|
| Toluidines | 1 | 2021 | 3 | 0.190 |
Why?
|
| DNA Viruses | 1 | 2021 | 6 | 0.190 |
Why?
|
| Nitriles | 1 | 2021 | 14 | 0.190 |
Why?
|
| Transfection | 2 | 2014 | 121 | 0.190 |
Why?
|
| Hydroxybutyrates | 1 | 2021 | 7 | 0.190 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2021 | 1 | 0.190 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 32 | 0.190 |
Why?
|
| Drug Resistance, Viral | 2 | 2020 | 13 | 0.180 |
Why?
|
| New York City | 1 | 2021 | 12 | 0.180 |
Why?
|
| Demyelinating Diseases | 3 | 2021 | 14 | 0.180 |
Why?
|
| Dyskinesias | 1 | 2021 | 10 | 0.180 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 474 | 0.180 |
Why?
|
| Herpesviridae Infections | 1 | 2001 | 1 | 0.180 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2001 | 1 | 0.180 |
Why?
|
| Herpesvirus 8, Human | 1 | 2001 | 1 | 0.180 |
Why?
|
| Herpesvirus 7, Human | 1 | 2001 | 2 | 0.180 |
Why?
|
| Herpesvirus 6, Human | 1 | 2001 | 3 | 0.180 |
Why?
|
| Pharmacovigilance | 1 | 2020 | 1 | 0.180 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2000 | 3 | 0.180 |
Why?
|
| Intracranial Embolism | 1 | 2020 | 4 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 10 | 0.180 |
Why?
|
| Morbidity | 1 | 2021 | 54 | 0.180 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2020 | 16 | 0.180 |
Why?
|
| Carbamazepine | 1 | 2020 | 6 | 0.180 |
Why?
|
| Bayes Theorem | 1 | 2021 | 42 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 278 | 0.170 |
Why?
|
| Meningitis, Viral | 1 | 2020 | 1 | 0.170 |
Why?
|
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2020 | 2 | 0.170 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2020 | 3 | 0.170 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2020 | 3 | 0.170 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2020 | 4 | 0.170 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2020 | 4 | 0.170 |
Why?
|
| Thrombophilia | 1 | 2020 | 6 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 39 | 0.170 |
Why?
|
| Cell Count | 3 | 2015 | 81 | 0.170 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 13 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 51 | 0.170 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 75 | 0.170 |
Why?
|
| Movement Disorders | 1 | 2020 | 66 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 89 | 0.170 |
Why?
|
| Risk | 2 | 2013 | 204 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 891 | 0.170 |
Why?
|
| Drugs, Essential | 1 | 2019 | 1 | 0.170 |
Why?
|
| World Health Organization | 1 | 2019 | 9 | 0.170 |
Why?
|
| Meningoencephalitis | 2 | 2013 | 9 | 0.170 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2019 | 8 | 0.170 |
Why?
|
| Consensus | 3 | 2023 | 87 | 0.170 |
Why?
|
| Gene Rearrangement | 2 | 2010 | 10 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 104 | 0.160 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 879 | 0.160 |
Why?
|
| Olive Oil | 1 | 2019 | 2 | 0.160 |
Why?
|
| Reagent Strips | 1 | 2019 | 3 | 0.160 |
Why?
|
| Urine | 2 | 2009 | 7 | 0.160 |
Why?
|
| Transplantation, Homologous | 2 | 2014 | 278 | 0.160 |
Why?
|
| Brain Ischemia | 1 | 2020 | 63 | 0.160 |
Why?
|
| Glutamate Decarboxylase | 1 | 2019 | 3 | 0.160 |
Why?
|
| Cerebellar Cortex | 1 | 2019 | 7 | 0.160 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 18 | 0.160 |
Why?
|
| Filgrastim | 1 | 2019 | 4 | 0.160 |
Why?
|
| Glucose | 1 | 2019 | 49 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 144 | 0.150 |
Why?
|
| Macaca fascicularis | 2 | 2015 | 25 | 0.150 |
Why?
|
| Oncogene Proteins, Viral | 2 | 1995 | 5 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 90 | 0.150 |
Why?
|
| Attention | 1 | 2019 | 124 | 0.150 |
Why?
|
| Gene Expression | 1 | 2019 | 199 | 0.150 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 55 | 0.150 |
Why?
|
| Viral Structural Proteins | 2 | 2009 | 3 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 3 | 2009 | 10 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 676 | 0.140 |
Why?
|
| Mianserin | 4 | 2016 | 8 | 0.140 |
Why?
|
| RNA, Viral | 4 | 2022 | 45 | 0.140 |
Why?
|
| Bell Palsy | 1 | 2017 | 2 | 0.140 |
Why?
|
| Cognition Disorders | 2 | 2014 | 985 | 0.140 |
Why?
|
| Recurrence | 5 | 2018 | 310 | 0.140 |
Why?
|
| Mass Screening | 3 | 2015 | 167 | 0.140 |
Why?
|
| Immune Evasion | 1 | 2017 | 2 | 0.140 |
Why?
|
| Toxoplasmosis | 2 | 2014 | 6 | 0.140 |
Why?
|
| Cryptococcosis | 2 | 2014 | 6 | 0.140 |
Why?
|
| Disease Management | 1 | 2017 | 102 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2007 | 3 | 0.130 |
Why?
|
| Fibroblasts | 2 | 2008 | 58 | 0.130 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2016 | 1 | 0.130 |
Why?
|
| Malformations of Cortical Development, Group I | 1 | 2016 | 2 | 0.130 |
Why?
|
| Myocarditis | 1 | 2016 | 12 | 0.130 |
Why?
|
| Interleukin-7 | 1 | 2016 | 12 | 0.130 |
Why?
|
| Proton-Translocating ATPases | 2 | 1995 | 4 | 0.130 |
Why?
|
| Myocardium | 1 | 2016 | 101 | 0.130 |
Why?
|
| Mutation | 2 | 2014 | 348 | 0.130 |
Why?
|
| Tremor | 2 | 2021 | 104 | 0.130 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 43 | 0.120 |
Why?
|
| Dermatologic Agents | 1 | 2015 | 7 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2017 | 261 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 30 | 0.120 |
Why?
|
| Cross Reactions | 2 | 2021 | 8 | 0.120 |
Why?
|
| Spinal Puncture | 1 | 2015 | 25 | 0.120 |
Why?
|
| Brain Waves | 1 | 2015 | 4 | 0.120 |
Why?
|
| In Situ Hybridization | 2 | 2006 | 49 | 0.120 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2014 | 6 | 0.120 |
Why?
|
| Brain Mapping | 1 | 2015 | 147 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2015 | 88 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 137 | 0.110 |
Why?
|
| Pancytopenia | 1 | 2014 | 3 | 0.110 |
Why?
|
| Interferon beta-1a | 1 | 2014 | 3 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 112 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2015 | 170 | 0.110 |
Why?
|
| Deltaretrovirus Infections | 1 | 1994 | 1 | 0.110 |
Why?
|
| Simian T-lymphotropic virus 1 | 1 | 1994 | 1 | 0.110 |
Why?
|
| Genes, env | 1 | 1994 | 1 | 0.110 |
Why?
|
| Neisseria meningitidis | 1 | 2014 | 2 | 0.110 |
Why?
|
| DNA, Protozoan | 1 | 2014 | 2 | 0.110 |
Why?
|
| DNA, Fungal | 1 | 2014 | 3 | 0.110 |
Why?
|
| Haplorhini | 1 | 1994 | 8 | 0.110 |
Why?
|
| Cryptococcus | 1 | 2014 | 3 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 1 | 2014 | 5 | 0.110 |
Why?
|
| Toxoplasma | 1 | 2014 | 7 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2014 | 147 | 0.110 |
Why?
|
| Cerebellar Ataxia | 1 | 2014 | 4 | 0.110 |
Why?
|
| Phylogeny | 3 | 2004 | 51 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2014 | 105 | 0.110 |
Why?
|
| DNA, Bacterial | 1 | 2014 | 43 | 0.110 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 39 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 30 | 0.110 |
Why?
|
| Gene Order | 1 | 2013 | 3 | 0.110 |
Why?
|
| Kinetics | 2 | 2006 | 188 | 0.110 |
Why?
|
| Blood Group Antigens | 1 | 2013 | 1 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2013 | 42 | 0.110 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 6 | 0.110 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 12 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 27 | 0.110 |
Why?
|
| Pons | 1 | 2013 | 5 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 107 | 0.110 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 6 | 0.110 |
Why?
|
| Antigens, Differentiation | 1 | 2013 | 10 | 0.110 |
Why?
|
| Retroviridae Proteins | 1 | 1993 | 1 | 0.110 |
Why?
|
| Microscopy, Electron | 2 | 2003 | 65 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 28 | 0.110 |
Why?
|
| Mice, SCID | 1 | 2013 | 42 | 0.110 |
Why?
|
| Cloning, Molecular | 3 | 2007 | 29 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2023 | 310 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2004 | 58 | 0.100 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 175 | 0.100 |
Why?
|
| Comorbidity | 2 | 2015 | 481 | 0.100 |
Why?
|
| Radiography | 2 | 2005 | 619 | 0.100 |
Why?
|
| Viral Core Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Genes, Regulator | 1 | 2012 | 3 | 0.100 |
Why?
|
| Alcoholic Intoxication | 1 | 2012 | 8 | 0.100 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 17 | 0.100 |
Why?
|
| Viral Tropism | 1 | 2012 | 4 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2010 | 36 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 56 | 0.100 |
Why?
|
| Macrophages | 1 | 1992 | 102 | 0.100 |
Why?
|
| Atrophy | 1 | 2012 | 91 | 0.100 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 18 | 0.090 |
Why?
|
| Antiprotozoal Agents | 1 | 2011 | 8 | 0.090 |
Why?
|
| Facial Hemiatrophy | 1 | 2011 | 1 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1368 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 80 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 124 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2008 | 175 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2007 | 61 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2002 | 107 | 0.090 |
Why?
|
| Antigens | 1 | 2010 | 11 | 0.090 |
Why?
|
| Spleen | 1 | 2010 | 30 | 0.090 |
Why?
|
| HLA-A3 Antigen | 1 | 2010 | 1 | 0.080 |
Why?
|
| HLA-B18 Antigen | 1 | 2010 | 1 | 0.080 |
Why?
|
| Serotyping | 1 | 2010 | 8 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 5 | 0.080 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 8 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 60 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2010 | 72 | 0.080 |
Why?
|
| Immunocompetence | 2 | 2011 | 6 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2010 | 116 | 0.080 |
Why?
|
| Outpatients | 1 | 2010 | 61 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 683 | 0.080 |
Why?
|
| Spinal Cord Diseases | 1 | 2010 | 47 | 0.080 |
Why?
|
| Blood | 1 | 2009 | 19 | 0.080 |
Why?
|
| Cerebral Angiography | 2 | 2020 | 33 | 0.080 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2009 | 13 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 19 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2009 | 50 | 0.080 |
Why?
|
| Inpatients | 1 | 2010 | 125 | 0.080 |
Why?
|
| Pregnancy | 1 | 2009 | 336 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 133 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2010 | 125 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2009 | 420 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2008 | 51 | 0.070 |
Why?
|
| Incidence | 2 | 2022 | 759 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 381 | 0.070 |
Why?
|
| Polycythemia Vera | 1 | 2007 | 1 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 31 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 181 | 0.070 |
Why?
|
| Leukocyte Common Antigens | 1 | 2007 | 6 | 0.070 |
Why?
|
| Receptors, CCR7 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Brain Neoplasms | 2 | 2002 | 86 | 0.070 |
Why?
|
| Receptors, Chemokine | 1 | 2007 | 9 | 0.070 |
Why?
|
| Dermatomyositis | 1 | 2006 | 12 | 0.070 |
Why?
|
| Myelin Sheath | 1 | 2006 | 26 | 0.060 |
Why?
|
| Cell Separation | 1 | 2005 | 25 | 0.060 |
Why?
|
| Cell Movement | 1 | 2006 | 80 | 0.060 |
Why?
|
| Alternative Splicing | 2 | 1997 | 22 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2006 | 257 | 0.060 |
Why?
|
| Open Reading Frames | 3 | 1997 | 9 | 0.060 |
Why?
|
| Crohn Disease | 1 | 2005 | 40 | 0.060 |
Why?
|
| Antigens, Polyomavirus Transforming | 2 | 2002 | 4 | 0.060 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2004 | 1 | 0.060 |
Why?
|
| Creatine | 1 | 2004 | 6 | 0.060 |
Why?
|
| Choline | 1 | 2004 | 4 | 0.060 |
Why?
|
| Plant Proteins | 1 | 2004 | 2 | 0.060 |
Why?
|
| Consensus Sequence | 1 | 2004 | 2 | 0.060 |
Why?
|
| Immunodominant Epitopes | 1 | 2004 | 4 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2004 | 25 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2004 | 15 | 0.060 |
Why?
|
| HeLa Cells | 2 | 1995 | 42 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2004 | 5 | 0.060 |
Why?
|
| Central Nervous System | 1 | 2004 | 55 | 0.060 |
Why?
|
| Mefloquine | 2 | 2016 | 2 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 125 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2004 | 59 | 0.060 |
Why?
|
| Heart | 1 | 2004 | 63 | 0.060 |
Why?
|
| Inclusion Bodies, Viral | 1 | 2003 | 1 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2003 | 31 | 0.050 |
Why?
|
| Muscle, Skeletal | 2 | 2004 | 383 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2003 | 41 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2023 | 4 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 52 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 20 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 46 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 17 | 0.050 |
Why?
|
| RNA Splicing | 2 | 1992 | 10 | 0.050 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2002 | 1 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2002 | 7 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 276 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 23 | 0.050 |
Why?
|
| Cystitis | 1 | 2002 | 12 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2022 | 7 | 0.050 |
Why?
|
| Anxiety | 1 | 2023 | 156 | 0.050 |
Why?
|
| Rural Population | 1 | 2022 | 22 | 0.050 |
Why?
|
| Homosexuality | 2 | 1993 | 6 | 0.050 |
Why?
|
| Epitope Mapping | 1 | 2021 | 1 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2002 | 81 | 0.050 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 2 | 0.050 |
Why?
|
| Vaccination | 1 | 2021 | 33 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 100 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1999 | 53 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2019 | 1890 | 0.050 |
Why?
|
| Nerve Growth Factor | 1 | 2001 | 36 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2001 | 42 | 0.050 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2021 | 2 | 0.050 |
Why?
|
| Fluorescent Treponemal Antibody-Absorption Test | 1 | 2021 | 2 | 0.050 |
Why?
|
| Income | 1 | 2022 | 80 | 0.050 |
Why?
|
| Reoperation | 3 | 2017 | 925 | 0.050 |
Why?
|
| Phrenic Nerve | 1 | 2021 | 2 | 0.050 |
Why?
|
| Serotonin Syndrome | 1 | 2021 | 1 | 0.050 |
Why?
|
| Diaphragm | 1 | 2021 | 8 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2021 | 77 | 0.050 |
Why?
|
| Myoclonus | 1 | 2021 | 9 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2020 | 5 | 0.040 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2020 | 11 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 29 | 0.040 |
Why?
|
| Brain Stem | 1 | 2020 | 19 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 34 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 2020 | 17 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 68 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 40 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2020 | 33 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2001 | 133 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 39 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 420 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 641 | 0.040 |
Why?
|
| Skin | 1 | 2001 | 123 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2020 | 87 | 0.040 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 3 | 0.040 |
Why?
|
| HTLV-I Infections | 3 | 1997 | 4 | 0.040 |
Why?
|
| Penicillins | 1 | 2019 | 9 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 1999 | 3 | 0.040 |
Why?
|
| Granulocytes | 1 | 1999 | 15 | 0.040 |
Why?
|
| Head | 1 | 2019 | 23 | 0.040 |
Why?
|
| Homosexuality, Male | 1 | 2019 | 28 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 300 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 56 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2021 | 227 | 0.040 |
Why?
|
| Monocytes | 1 | 1999 | 61 | 0.040 |
Why?
|
| Neurobiology | 1 | 2019 | 5 | 0.040 |
Why?
|
| Gait | 1 | 2022 | 412 | 0.040 |
Why?
|
| Vacuoles | 2 | 1995 | 7 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 167 | 0.040 |
Why?
|
| Linear Models | 1 | 1999 | 247 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 44 | 0.040 |
Why?
|
| Cell Transformation, Viral | 2 | 1997 | 2 | 0.040 |
Why?
|
| Phlebography | 1 | 2017 | 10 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 29 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1994 | 36 | 0.030 |
Why?
|
| Species Specificity | 2 | 1994 | 42 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2017 | 39 | 0.030 |
Why?
|
| Gene Products, rex | 2 | 1997 | 2 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 766 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 158 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2016 | 4 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 458 | 0.030 |
Why?
|
| Heart Block | 1 | 2016 | 5 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 19 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 1996 | 1 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2016 | 65 | 0.030 |
Why?
|
| Eye Movements | 1 | 1996 | 11 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2016 | 68 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 100 | 0.030 |
Why?
|
| Mesencephalon | 1 | 1996 | 24 | 0.030 |
Why?
|
| Melanoma | 1 | 2016 | 60 | 0.030 |
Why?
|
| Myositis | 1 | 2016 | 33 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 1995 | 21 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 32 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2015 | 130 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 415 | 0.030 |
Why?
|
| Cercopithecidae | 1 | 1994 | 1 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 1994 | 3 | 0.030 |
Why?
|
| Cytoplasmic Granules | 1 | 2014 | 5 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 8 | 0.030 |
Why?
|
| Pan troglodytes | 1 | 1994 | 8 | 0.030 |
Why?
|
| Electronystagmography | 2 | 1991 | 2 | 0.030 |
Why?
|
| Audiometry | 2 | 1991 | 5 | 0.030 |
Why?
|
| Rituximab | 1 | 2014 | 48 | 0.030 |
Why?
|
| HTLV-I Antigens | 1 | 1993 | 1 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1993 | 8 | 0.030 |
Why?
|
| White Matter | 1 | 2015 | 134 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 214 | 0.030 |
Why?
|
| Leukemia, T-Cell | 1 | 1992 | 1 | 0.030 |
Why?
|
| Paraparesis, Tropical Spastic | 1 | 1992 | 1 | 0.030 |
Why?
|
| HIV Core Protein p24 | 1 | 1992 | 10 | 0.030 |
Why?
|
| Genes, Overlapping | 1 | 1992 | 1 | 0.030 |
Why?
|
| Gene Products, tax | 1 | 1992 | 1 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 5 | 0.030 |
Why?
|
| Gene Products, env | 1 | 1992 | 14 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2014 | 133 | 0.020 |
Why?
|
| Oligoclonal Bands | 1 | 2011 | 1 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2011 | 8 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2013 | 347 | 0.020 |
Why?
|
| Vasculitis | 1 | 1991 | 26 | 0.020 |
Why?
|
| Hearing Disorders | 1 | 1991 | 2 | 0.020 |
Why?
|
| United States | 1 | 2017 | 2035 | 0.020 |
Why?
|
| Vestibular Diseases | 1 | 1991 | 4 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 186 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 1196 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1991 | 35 | 0.020 |
Why?
|
| Evoked Potentials, Visual | 1 | 1990 | 1 | 0.020 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1990 | 7 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1990 | 35 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 8 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2008 | 89 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2007 | 5 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cytarabine | 1 | 2006 | 11 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 1339 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 245 | 0.020 |
Why?
|
| Peptides | 1 | 2007 | 102 | 0.020 |
Why?
|
| Cytokines | 1 | 2007 | 222 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2004 | 7 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2004 | 28 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2004 | 68 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 41 | 0.010 |
Why?
|
| Endothelium | 1 | 2001 | 14 | 0.010 |
Why?
|
| Edema | 1 | 2001 | 25 | 0.010 |
Why?
|
| Muscle Weakness | 1 | 2001 | 34 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2001 | 483 | 0.010 |
Why?
|
| Didanosine | 1 | 1997 | 3 | 0.010 |
Why?
|
| Zidovudine | 1 | 1997 | 13 | 0.010 |
Why?
|
| Hearing Tests | 1 | 1997 | 10 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1997 | 64 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1997 | 406 | 0.010 |
Why?
|
| Blepharoptosis | 1 | 1996 | 1 | 0.010 |
Why?
|
| Convergence, Ocular | 1 | 1996 | 1 | 0.010 |
Why?
|
| Exotropia | 1 | 1996 | 1 | 0.010 |
Why?
|
| Ophthalmoplegia | 1 | 1996 | 2 | 0.010 |
Why?
|
| Americas | 1 | 1994 | 1 | 0.010 |
Why?
|
| Bovine papillomavirus 1 | 1 | 1993 | 1 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1993 | 9 | 0.010 |
Why?
|
| AIDS-Related Complex | 1 | 1991 | 2 | 0.010 |
Why?
|
| Vestibular Function Tests | 1 | 1991 | 2 | 0.010 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 1991 | 4 | 0.010 |
Why?
|